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in patients with acute STEMI.
OBJECTIVES The aim of this study was to evaluate the stent thrombosis (ST) rate up to 3 years in patients with
ST-segment elevation myocardial infarction (STEMI) treated by primary percutaneous coronary intervention (PCI) with
new-generation drug-eluting stents (n-DES) compared with bare-metal stents (BMS) and old-generation drug-eluting
stents (o-DES) enrolled in the SCAAR (Swedish Coronary Angiography and Angioplasty Registry).
METHODS From January 2007 to January 2013, 34,147 patients with STEMI were treated by PCI with n-DES (n ¼ 4,811),
o-DES (n ¼ 4,271), or BMS (n ¼ 25,065). The risks of early/late (up to 1 year) and very late deﬁnite ST (after 1 year) were
estimated.
RESULTS Cox regression landmark analysis showed a signiﬁcantly lower risk of early/late ST in patients treated with
n-DES (hazard ratio [HR]: 0.65; 95% conﬁdence interval [CI]: 0.43 to 0.99; p ¼ 0.04) and o-DES (HR: 0.60; 95%
CI: 0.41 to 0.89; p ¼ 0.01) compared with the BMS group. The risk of very late ST was similar between the n-DES
and BMS groups (HR: 1.52; 95% CI: 0.78 to 2.98; p ¼ 0.21), whereas a higher risk of very late ST was observed with
o-DES compared with BMS (HR: 2.88; 95% CI: 1.70 to 4.89; p < 0.01).
CONCLUSIONS Patients treated with n-DES have a lower risk of early/late ST than patients treated with BMS. The risk
of very late ST is low and comparable between n-DES and BMS up to 3 years of follow-up, whereas o-DES treatment is
associated with an increased risk of very late ST. The current STEMI guidelines might require an update in light of the
results of this and other recent studies. (J Am Coll Cardiol 2014;64:16–24) © 2014 by the American College of Cardiology
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ABB R E V I A T I O N S
AND ACRONYMS
BMS = bare-metal stent(s)
CI = conﬁdence interval
DAPT = dual-antiplatelet
therapy
DES = drug-eluting stent(s)
HR = hazard ratio
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17D rug-eluting stents (DES) have been shownto signiﬁcantly reduce the rate of restenosisand target lesion revascularization (1,2),
and consequently, their use has been commonly
extended to complex lesions and acute clinical set-
tings (3–6). Concerns have been raised and still not
resolved about the long-term safety of DES in patients
with acute ST-segment elevation myocardial infarc-
tion (STEMI).100%
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FIGURE 1 Distribution of the Use of n-DES, o-DES, and BMS During the
Study Period
The use of new-generation drug-eluting stents (n-DES) increased from 10% in
2009 to 85% in 2012. The use of bare-metal stents (BMS) decreased from 50%
in 2007 to 15% in 2012. The use of old-generation drug-eluting stents (o-DES)
decreased from 50% in 2007 to 0.1% in 2012.
SEE PAGE 25
n-DES = new-generation
drug-eluting stent(s)
o-DES = old-generation
drug-eluting stent(s)
PES = paclitaxel-eluting
stent(s)
SES = sirolimus-eluting
stent(s)
ST = stent thrombosis
STEMI = ST-segment elevation
ardial infarctionPlatelet activation is increased in patients with
STEMI (7,8). Moreover, a delay in arterial healing has
been recognized at the culprit site in patients with
STEMI compared with patients treated for stable
angina (9). Percutaneous coronary intervention (PCI)
in STEMI patients is therefore associated with a
higher risk of stent thrombosis (ST) (10–12).
Comparisons of new-generation DES (n-DES) and
bare-metal stents (BMS) in the STEMI setting (13–15)
are limited. The available data on the outcome of PCI
in STEMI patients are mainly based on comparisons of
old-generation DES (o-DES) and BMS (16–22).
The objective of this study was to evaluate the
ST rate up to 3 years in patients with STEMI treated
by PCI with n-DES compared with BMS and o-DES
documented in a national registry with complete
consecutive enrollment, the SCAAR (Swedish Coro-
nary Angiography and Angioplasty Registry).
METHODS
All consecutive patients in Sweden with STEMI un-
dergoing primary PCI from January 2007 to January
2013 were included. The n-DES group included the
Endeavor Resolute (Medtronic Inc., Minneapolis,
Minnesota); Xience V and Xience Prime (Abbott
Vascular, Santa Clara, California); Promus and Promus
Element (Boston Scientiﬁc, Natick, Massachusetts).
The o-DES group included the Cypher and Cypher
Select (Cordis Corporation, Miami, Florida), Taxus
Express and Taxus Liberté (Boston Scientiﬁc), and
Endeavor (Medtronic). The BMS group included the
Multilink Vision, Multilink MiniVision, Multilink 8,
and Multilink Flexmaster (Abbott Vascular); Driver,
Micro Driver coronary, and Integrity (Medtronic);
Liberté (Boston Scientiﬁc); Braun Coroﬂex Blue
(B. Braun, Melsungen, Germany); and Chrono stent
(CID, Saluggia, Italy). The choice of stent type was at
the operator’s discretion.
Deﬁnite ST was deﬁned according to the Academic
Research Consortium deﬁnition (23).
STATISTICAL ANALYSIS. Continuous variables are
expressed as mean  SD and discrete variablesas percentages. Differences in means among
groups were analyzed by a 2-sided t test or by
1-way analysis of variance using a Tukey-
Kramer test to compare all pairs. Categorical
variables are expressed as absolute numbers
and percentages. Differences in categorical
variableswere analyzed by the chi-square test.
The predeﬁned primary endpoint was to
evaluate the ST rate after the implantation of
n-DES, o-DES, and BMS in STEMI patients.
The log-minus-log test was used to assess the
proportional hazard assumption. Analyses
were based on the ﬁrst recorded procedure
during the inclusion period to avoid dupli-
cate entries. For patients receiving several
stents during the same procedure, only 1
stent was randomly selected and followed
over time. Patients with cardiogenic shock
were excluded.The cumulative adjusted hazard risk (HR) of ST
up to 3 years was calculated using Cox proportional
hazard method. The Cox analysis models were
censored up to 3 years. Propensity score analysis was
used to compensate for the nonrandomized nature
of this study. The propensity score models were
deﬁned as the conditional probability of receiving a
myoc
TABLE 1 Baseline Characteristics (N ¼ 34,147)
Variable
n-DES*
(n ¼ 4,811)
o-DES†
(n ¼ 4,271)
BMS
(n ¼ 25,065)
Women 1,295 (26.9) 1,119 (26.2) 7,183 (28.7)
Body mass index, kg/m2 27.1  4.5 27.08  4.3 26.7  5.2
Age, yrs 65.8  10.9 66.1  11.2 67.3  12.1
Hypertension 2,181 (45.3) 1,968 (46.1) 9,994 (39.9)
Diabetes mellitus 862 (18.0) 879 (20.6) 2,979 (11.5)
Insulin treatment 406 (8.4) 395 (9.2) 1,176 (4.7)
Noninsulin treatment 451 (9.4) 483 (11.3) 1,668 (10.3)
Unknown treatment 57 (1.2) 43 (1.0) 370 (1.5)
Hypercholesterolemia 1,270 (26.4) 1,211 (28.4) 4,744 (18.6)
Smoking status
Former smoker 1,329 (27.6) 1,237 (29.0) 6,313 (25.2)
Current smoker 1,393 (29.0) 1,189 (27.8) 7,171 (28.6)
Previous MI 817 (17.0) 834 (19.5) 3,072 (12.3)
Previous CABG 204 (4.2) 198 (4.6) 764 (3.0)
Values are n (%) or mean  SD. *p value for n-DES versus o-DES <0.05 for diabetes mellitus, smoking status,
previous MI. †p value for o-DES versus BMS <0.05 for all variables.
BMS ¼ bare-metal stent(s); CABG ¼ coronary artery bypass grafting; MI ¼ myocardial infarction; n-DES ¼
new-generation drug-eluting stent(s); o-DES ¼ old-generation drug-eluting stent(s).
TABLE 2 Procedural Characteristics (N ¼ 34,147)
Variable
n-DES*
(n ¼ 4,811)
o-DES†
(N ¼ 4,271)
BMS
(n ¼ 25,065)
No. of stents per procedure 1.96  1.10 1.96  1.08 1.78  0.99
Stent diameter, mm 2.96  0.46 3.01  0.50 3.16  0.49
Total stent length, mm 20.08  7.37 20.10  7.19 17.85  5.78
Treated vessel
RCA 1,551 (32.2) 1,435 (33.6) 11,051 (44.1)
Left main 73 (1.5) 91 (2.1) 154 (0.6)
LAD 2,406 (47.8) 2,041 (47.8) 10,002 (39.9)
LCX 699 (14.5) 621 (14.5) 3,544 (14.1)
CABG 82 (1.7) 83 (1.9) 314 (1.2)
Bifurcation lesions 616 (12.8) 494 (11.6) 1,941 (7.8)
3-vessel disease 859 (17.9) 763 (17.9) 4,750 (19)
Procedural success 4,741 (98.5) 4,174 (97.7) 24,591 (98.1)
Medications before PCI
ASA 4,203 (87.4) 3,702 (86.7) 21,394 (85.4)
Clopidogrel 3,010 (62.6) 2,393 (56.0) 18,134 (72.3)
Ticagrelor 493 (17.7) 874 (37.4) 797 (12.4)
Bivalirudin 36 (0.7) 22 (0.5) 88 (0.4)
GP IIb/IIIa 111 (2.3) 131 (3.1) 1,237 (4.9)
Heparin 6,858 (27.4) 1,552 (36.3) 1,960 (40.7)
LMWH 136 (2.8) 170 (4.0) 2,128 (8.5)
Medications during PCI
ASA 514 (10.7) 515 (12.0) 3,233 (12.9)
Clopidogrel 1,115 (23.2) 983 (23.0) 5,727 (22.8)
Ticagrelor 363 (13.8) 434 (20.2) 513 (11.7)
Bivalirudin 3,168 (65.8) 2,583 (60.5) 11,296 (45.1)
GP IIb/IIIa 1,170 (24.3) 1,332 (31.2) 10,878 (43.4)
Heparin 2,599 (54.0) 2,322 (54.4) 14,616 (58.3)
LMWH 188 (3.9) 188 (4.4) 1,265 (5.0)
Values are mean  SD or n (%). *p value for n-DES versus o-DES: <0.05 for clopidogrel, ticagrelor, heparin,
LMWH before PCI, ticagrelor, bivalirudin, GP IIb/IIIa during PCI. †p value for o-DES versus BMS: <0.05 for all
variables unless bivalirudin before PCI.
ASA¼acetylsalicylic acid;GP¼glycoprotein;LAD¼ left anteriordescendingartery; LCX¼ left circumﬂexartery;
LMWH ¼ low molecular weight heparin; PCI ¼ percutaneous coronary intervention; RCA ¼ right coronary artery.
Sarno et al. J A C C V O L . 6 4 , N O . 1 , 2 0 1 4
New-Generation DES in STEMI J U L Y 8 , 2 0 1 4 : 1 6 – 2 4
18DES (n-DES or o-DES) or a BMS on the basis of
available variables and were estimated with a multi-
ple logistic regression model. The pre-speciﬁed vari-
ables included in the 3 propensity score models for
the different comparisons were age, sex, diabetes,
hypertension, dyslipidemia, smoking status, use of
acetylsalicylic acid, glycoprotein IIb/IIIa inhibitors,
and/or P2Y12 receptor inhibitors at the index proce-
dure, treated vessel, previous myocardial infarction,
previous coronary artery bypass grafting, previous
PCI, year of the index procedure, enrolling center,
lesion type, bifurcation lesions, and 3-vessel/left
main disease.
The C-index for the ability of propensity score
to differentiate o-DES and n-DES from BMS and o-DES
from n-DES was 0.92, 0.91, and 0.87, respectively.
Adjusted relative risks in the n-DES, o-DES, and
BMS groups were estimated with the use of Cox
regression models in which the propensity score and
the stent group were entered as covariates.
All reported p values are 2-sided. All analyses were
performed with the use of SPSS statistical software
(version 19.0, SPSS Inc., Chicago, Illinois).
RESULTS
During the study period, 34,147 patients with
STEMI were treated by PCI with n-DES (n ¼ 4,811),
o-DES (n ¼ 4,271), or BMS (n ¼ 25,065). The relative
distribution of n-DES, o-DES, and BMS during the
study period is described in Figure 1.
Baseline characteristics are listed in Table 1. The
clinical risk proﬁle was higher in the DES groups
compared with the BMS group with no relevant dif-
ferences between the n-DES and o-DES groups.
Procedural characteristics are shown in Table 2.
Ticagrelor was more often used in the o-DES group,
whereas lower use of bivalirudin was observed in the
BMS group. Also, glycoprotein IIb/IIIa inhibitors were
more often used with BMS.
The assumption of proportionality of the hazards
for ST during the 3-year follow-up period was not met
(p ¼ 0.07). Therefore, we performed a landmark anal-
ysis with a pre-speciﬁed landmark set at 1 year
to provide separate descriptions of the early/late (up to
1 year) and very late risks of ST (>1 year) events. The
total number of events of deﬁnite ST up to 3 years was
544. The cumulative rates of ST up to 3 years in the
n-DES, o-DES, and BMS groups are shown in Figure 2.
EARLY/LATE ST. Cox regression landmark analysis
adjusted by propensity score showed a signiﬁcantly
lower risk of early/late ST in the n-DES and o-DES
groups compared with the BMS group. There was no
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FIGURE 2 Cumulative Rates of Deﬁnite Stent Thrombosis Up to 3 Years in the n-DES, o-DES, and BMS Groups
The curves showing the cumulative rates of stent thrombosis in the n-DES and o-DES groups start to diverge before 6 months post-
percutaneous coronary intervention (PCI) with a further step-up in the o-DES group after 1 year. The rates of stent thrombosis in the BMS group
increased constantly up to 3 years. Abbreviations as in Figure 1.
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19signiﬁcant difference between n-DES and o-DES in
the risk of early/late ST (Fig. 3, Table 3).
Cox regression analysis showed no statistically
signiﬁcant impact of bivalirudin use (HR: 1.17; 95%
conﬁdence interval [CI]: 0.93 to 1.46), glycoprotein
IIb/IIIa inhibitors (HR: 0.95; 95% CI: 0.74 to 1.22), and
ticagrelor (HR: 1.09; 95% CI: 0.49 to 2.39) on the early
ST risk up to 30 days.
VERY LATE ST. There was no signiﬁcant difference in
the risk of very late ST between the n-DES group and
the BMS group, whereas a higher risk of very late ST
was observed in the o-DES group compared with the
BMS group. There was no signiﬁcant difference be-
tween the n-DES and o-DES groups in the risk of very
late ST (Fig. 3, Table 3).
ALL-CAUSE MORTALITY. The total number of events
of death up to 3 years was 3,579. The cumulative rates
of death up to 3 years in the n-DES, o-DES, and BMS
groups are shown in Figure 4.
The risk of death was signiﬁcantly and constantly
lower in the n-DES (adjusted HR: 0.55; 95% CI: 0.48to 0.62) and o-DES (adjusted HR: 0.58; 95% CI: 0.52
to 0.65) groups compared with the BMS group. No
signiﬁcant differences were observed between the
n-DES and o-DES groups (adjusted HR: 1.05; 95%
CI: 0.89 to 1.24).
DISCUSSION
The main ﬁndings of this study were as follows: 1) a
signiﬁcant lower risk of ST during the ﬁrst year after
PCI with both n-DES and o-DES compared with BMS,
but a higher risk of very late ST up to 3 years in the o-
DES group compared with the BMS group; and 2) a
similar risk of very late ST in the n-DES and BMS
groups.
Differently from the previously published results
of an unselected all-comers population of the SCAAR
(24), in this population of STEMI patients enrolled
consecutively in the SCAAR, a signiﬁcantly lower risk
of ST in both the n-DES and o-DES groups was
observed only during the ﬁrst year after PCI, with an
ST rate at 1 year of 0.9% in the n-DES group versus
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FIGURE 3 Landmark Analysis of Deﬁnite Stent Thrombosis in n-DES,
o-DES, and BMS
The curves showing the cumulative rates of very late stent thrombosis are
similar in n-DES and BMS. Very late stent thrombosis rate is signiﬁcantly higher
with o-DES compared with BMS. Although the rate of very late stent throm-
bosis up to 3 years is lower in n-DES compared with o-DES, no signiﬁcant dif-
ference between n-DES and o-DES was observed. Abbreviations as in Figure 1.
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201.1% in the o-DES group and 1.5% in the BMS group.
The ST rate in the o-DES group increased by 0.6%
during the second year and by 0.4% during the third
year of follow-up. The very late ST risk up to 3 years
was more than doubled in the o-DES group compared
with the BMS group.
Most previous randomized studies (19,22,25,26)
failed to show any signiﬁcant difference in the ST
risk between DES and BMS, and this could be related
to the limited statistical power inadequate to detect a
small but statistically signiﬁcant difference in low-
frequency events such as ST.
In the HORIZONS-AMI (Harmonizing Outcomes
With Revascularization and Stents in Acute Myocar-
dial Infarction) study (22), the use of paclitaxel-
eluting stents (PES) was associated with a statisticallyTABLE 3 Adjusted Risks of Deﬁnite Stent Thrombosis
n-DES vs. BMS
Early/late ST HR: 0.65; 95% CI: 0.43–0.99; p ¼ 0.04 HR: 0.60; 9
Very late ST HR: 1.52; 95% CI: 0.78–2.98; p ¼ 0.21 HR: 2.88; 9
CI ¼ conﬁdence interval; HR ¼ hazard ratio; ST ¼ stent thrombosis; other abbreviationssigniﬁcant decrease in in-stent restenosis, whereas no
differences in STwere observed in up to 2 years follow-
up. Other smaller randomized, ﬁrst-generation DES/
BMS studies (16,20,21,27) found similar results,
with reduced rates of repeat revascularization in
ﬁrst-generation DES and no difference between ﬁrst-
generation DES and BMS in the risk of ST up to 4 and
5 years. However, in the TYPHOON (Trial to Assess the
Use of the CYPHer Sirolimus-Eluting Coronary Stent in
Acute Myocardial Infarction Treated With BallOON
Angioplasty) study (16), although the overall rate of ST
up to 4 yearswas similar between the sirolimus-eluting
stent (SES) group and the BMS group (3.6% vs. 4.0%,
respectively), the rate of very late ST was numerically
higher in the SES group (2.0% vs. 0.8%) without
reaching statistical signiﬁcance. Similarly, in the PAS-
SION (Paclitaxel-Eluting Versus Conventional Stent in
Myocardial Infarction with ST-Segment Elevation)
study (28), the rates of late/very late ST were 3.2%
in patients treated with PES versus 1.1% in the BMS
group (p ¼ 0.09). Data from a single-center registry of
1,738 patients with STEMI (29) also showed a very late
ST rate of 2.7% in a group of patients treated with SESs
compared with 0.9% in patients treated with PES,
whereas no cases of STwere observed in the BMS group
at a median follow-up of 3 years.
Consistent with these ﬁndings, a recent meta-
analysis on 6,270 patients with STEMI from 11 ran-
domized studies (30) also found a higher rate of very
late ST in patients treated with o-DES compared with
patients treated with BMS.
Our ﬁnding of a higher risk of very late ST in the
o-DES group compared with the BMS group conﬁrms
concerns about the use of o-DES in the STEMI setting,
which have led to a Class IIA recommendation for the
use of DES in the current STEMI guidelines (31).
Looking at Figure 1, the ST rates deviate after the
ﬁrst days of follow-up with an early ST rate (up to 30
days) of 0.5% and 0.6% in the n-DES and o-DES
groups, respectively, versus 0.9% in the BMS group.
As a multifactorial event, ST is difﬁcult to differen-
tiate between patient characteristics, lesion, and
procedural precipitating factors and features associ-
ated with the device.
Our ﬁnding of a lower risk of ST in patients treated
with o-DES during the ﬁrst year of follow-up and ao-DES vs. BMS n-DES vs. o-DES
5% CI: 0.41–0.89; p ¼ 0.01 HR: 0.73; 95% CI: 0.44–1.21; p ¼ 0.22
5% CI: 1.70–4.89; p < 0.01 HR: 0.77; 95% CI: 0.23–1.47; p ¼ 0.35
as in Table 1.
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FIGURE 4 Cumulative Rates of All-Cause Mortality Up to 3 Years in the n-DES, o-DES, and BMS Groups
The curves showing the cumulative rates of all-cause mortality show a higher mortality rate with BMS compared with n-DES and o-DES.
No signiﬁcant differences were observed between n-DES and o-DES. DAPT ¼ dual-antiplatelet therapy; ST ¼ stent thrombosis; STEMI ¼
ST-segment elevation myocardial infarction; other abbreviations as in Figure 1.
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21higher risk of very late ST compared with patients
treated with BMS align with a previous meta-analysis
(32) from 15 randomized, controlled trials (n ¼ 7,867)
comparing ﬁrst-generation U.S. Food and Drug
Administration–approved DES with BMS in patients
with STEMI. In this meta-analysis, the early beneﬁts
of ﬁrst-generation DES in reducing repeat revascu-
larization and ST were offset by an increase in
very late ST, and the authors suggest time-dependent
effects of ﬁrst-generation DES for ST. These ﬁnd-
ings support the hypothesis of 2 opposite, time-
dependent effects that have been described for
polymers used in DES technology—an early protec-
tive effect against ST and a late proinﬂammatory and
prothrombotic effect. Recent studies on biodegrad-
able polymers used in newer-generation DES (15)
suggest the possibility of obtaining the early advan-
tages of polymers while avoiding the very late haz-
ards, which may be especially useful in patients with
STEMI.
Unfortunately, we continue to lack data on the
long-term duration of the dual-antiplatelet therapy(DAPT). In STEMI patients, the standard recommen-
dation for DAPT was 1 year in both the DES and the
BMS groups. However, it is unlikely that the DAPT
duration has affected the results of very late ST.
The early cessation of DAPT and other procedural
factors, such as stent underexpansion, malap-
position, and lesion complexity, are known to
contribute mainly to the development of early and
late ST (33). Very late ST seems more likely linked
to impaired vessel healing (34,35), secondary to
a chronic inﬂammatory response elicited by the
permanent polymer and/or to accelerated neo-
atherosclerosis (36,37) (Central Illustration).
In the current study, n-DES were associated with
a lower risk of ST at 1 year and the risk of very late
ST up to 3 years was similar to BMS. A similar risk of
overall and very late ST between everolimus-eluting
stents and BMS up to 2 years of follow-up was re-
ported in a recent meta-analysis on 14,740 patients
with STEMI from 28 randomized, controlled trials
(38). In contrast, we found no statistically signiﬁ-
cant difference in the risk of ST between patients
CENTRAL ILLUSTRATION STEMI Patients Can Have an Increased Risk of ST Due to Increased Platelet Activity and
Delayed Healing at the Culprit Site
Early/late ST seems to be more linked to lesion complexity, DAPT cessation, and suboptimal stent deployment. Very late ST might be linked to
chronic inﬂammation elicited by the polymer, a possible toxic effect of the eluting drug, or accelerated neo-atherosclerosis. DAPT ¼ dual-
antiplatelet therapy; DES ¼ drug-eluting stent(s); ST ¼ stent thrombosis; STEMI ¼ ST-segment elevation myocardial infarction.
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22treated with n-DES or o-DES. Most likely, this could
relate to a smaller number of patients treated with
o-DES and n-DES during the study period, and the
sample size might still be inadequate to determine a
signiﬁcant difference due to the low frequency of
the event.
Although BMS have been proved to be safe in STEMI
patients (39,40) and the improvements of the new
stent platforms have reduced restenosis rates, DES are
superior in terms of a decrease in restenosis occur-
rence. Our study shows that n-DES are associated with
a low risk of ST even on long-term follow-up.
The advantages of o-DES over BMS at 1 year of
follow-up in terms of ST are counterbalanced by a
higher risk of very late ST.
The constantly signiﬁcant higher mortality during
the 3-year follow-up in the BMS group compared with
the n-DES and o-DES groups cannot be simply
explained by our ST ﬁndings.
STUDY LIMITATIONS. There are intrinsic limitations
to registry data, such as differences in baseline char-
acteristics and/or selection bias, which might
not have been recorded, as well as time-dependent
changes in outcome.
The deﬁnition of hypercholesterolemia, hyperten-
sion, and diabetes in the SCAAR is “medically
treated” hypercholesterolemia, hypertension, and
diabetes. Therefore, the actual incidence of these
factors might have been underestimated.Althoughweused a propensity score analysis to take
into account possible factors related to patient and
procedural characteristics and time,we cannot rule out
the presence of selection bias and other unknown
patient/procedure-related factors that could affect the
outcome in this population. ST is a low-frequency
event that can signiﬁcantly affect the individual
outcome (41,42), but it is less probable to affect the
overall mortality in a large population.
Another limitation of the present study is the
lack of information about the medical therapy during
the follow-up and the duration and doses of P2Y12
receptor inhibition treatment in individual patients.CONCLUSIONS
This study shows that the use of new-generation DES
in STEMI patients undergoing PCI is safe in short- and
long-term follow-up, with a lower risk of early/late ST
and a low risk of very late ST, similar to BMS. The
current guidelines on STEMI might require an update
in light of the results of this and other recent studies
(13–15,38).
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PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE 1:
The use of new-generation DES in patients with STEMI
undergoing percutaneous coronary intervention is safe on
short- and long-term follow-up with a lower risk of early/
late stent thrombosis and a low risk of very late stent
thrombosis, similar to BMS.
COMPETENCY IN MEDICAL KNOWLEDGE 2:
Our ﬁnding of a higher risk of very late stent thrombosis
in the older-generation DES group compared with the
BMS group conﬁrms concerns about the use of older-
generation DES in the STEMI setting that have led to a
Class IIA recommendation for the use of DES in the
current STEMI guidelines.
TRANSLATIONAL OUTLOOK: The current guidelines
on STEMI might require an update in light of the results of
this and other recent studies.
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